![]() |
Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer
Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.
More... |
| All times are GMT -7. The time now is 08:57 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021